The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.
 
Ross Erik Krasnow
No Relationships to Disclose
 
Thomas Seisen
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Morgan Roupret
No Relationships to Disclose
 
Jeffrey J. Leow
No Relationships to Disclose
 
Stuart R. Lipsitz
No Relationships to Disclose
 
Malte Vetterlein
No Relationships to Disclose
 
Mark A Preston
No Relationships to Disclose
 
Nawar Hanna
No Relationships to Disclose
 
Adam S. Kibel
Honoraria - Dendreon; MTG Therapeutics; profound; Sanofi; Tokai Pharmaceuticals
 
Maxine Sun
No Relationships to Disclose
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
Quoc-Dien Trinh
No Relationships to Disclose
 
Steven Lee Chang
No Relationships to Disclose